The effectiveness of dexamethasone on the prognosis of dialysis patients with severe COVID-19
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Revista da Associação Médica Brasileira (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302021001001299 |
Resumo: | SUMMARY OBJECTIVE: This study aimed to investigate the effectiveness of dexamethasone in dialysis patients with COVID-19 and whether it predicts mortality. METHODS: This is a comparative cross-sectional study of 113 consecutive patients with COVID-19 with severe pneumonia signs. The patients were divided into two groups according to the use of dexamethasone treatment: group 1 (n=45) included patients who were treated with dexamethasone and group 2 (n=68) who did not receive dexamethasone. RESULTS: The mean age of both groups was 67.0±10.6 and 67.2±13.0 years, respectively (p=0.947). With respect to demographic and laboratory findings, there were no significant differences between the two groups (p>0.05). The hospitalization time of patients in group 1 was longer than that in group 2 (11 [7–17] days vs. 8 [5.3–14] days, p=0.093]. The 28-day survival rate was 54.2% in the group receiving dexamethasone treatment and 79.5% in the group not receiving dexamethasone treatment (p=0.440). CONCLUSION: Dexamethasone did not reduce mortality rates and the requirement for intensive care unit in dialysis patients with COVID-19. Larger prospective randomized clinical trials are required to associate personalized medicine with the corticosteroid treatment to select suitable patients who are more likely to show a benefit. |
id |
AMB-1_1b6b923137c70e56ec3632b9f2751c64 |
---|---|
oai_identifier_str |
oai:scielo:S0104-42302021001001299 |
network_acronym_str |
AMB-1 |
network_name_str |
Revista da Associação Médica Brasileira (Online) |
repository_id_str |
|
spelling |
The effectiveness of dexamethasone on the prognosis of dialysis patients with severe COVID-19Chronic kidney diseaseCOVID-19DexamethasoneDialysisMortalitySUMMARY OBJECTIVE: This study aimed to investigate the effectiveness of dexamethasone in dialysis patients with COVID-19 and whether it predicts mortality. METHODS: This is a comparative cross-sectional study of 113 consecutive patients with COVID-19 with severe pneumonia signs. The patients were divided into two groups according to the use of dexamethasone treatment: group 1 (n=45) included patients who were treated with dexamethasone and group 2 (n=68) who did not receive dexamethasone. RESULTS: The mean age of both groups was 67.0±10.6 and 67.2±13.0 years, respectively (p=0.947). With respect to demographic and laboratory findings, there were no significant differences between the two groups (p>0.05). The hospitalization time of patients in group 1 was longer than that in group 2 (11 [7–17] days vs. 8 [5.3–14] days, p=0.093]. The 28-day survival rate was 54.2% in the group receiving dexamethasone treatment and 79.5% in the group not receiving dexamethasone treatment (p=0.440). CONCLUSION: Dexamethasone did not reduce mortality rates and the requirement for intensive care unit in dialysis patients with COVID-19. Larger prospective randomized clinical trials are required to associate personalized medicine with the corticosteroid treatment to select suitable patients who are more likely to show a benefit.Associação Médica Brasileira2021-09-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302021001001299Revista da Associação Médica Brasileira v.67 n.9 2021reponame:Revista da Associação Médica Brasileira (Online)instname:Associação Médica Brasileira (AMB)instacron:AMB10.1590/1806-9282.20210600info:eu-repo/semantics/openAccessToçoglu,AyselDheir,HamadDemirci,TanerKurt,RumeysaSalihi,SalihYaylaci,SelçukÇakar,Gözde ÇakırsoyToptan,HandeKarabay,OguzSipahi,Savaseng2021-11-17T00:00:00Zoai:scielo:S0104-42302021001001299Revistahttps://ramb.amb.org.br/ultimas-edicoes/#https://old.scielo.br/oai/scielo-oai.php||ramb@amb.org.br1806-92820104-4230opendoar:2021-11-17T00:00Revista da Associação Médica Brasileira (Online) - Associação Médica Brasileira (AMB)false |
dc.title.none.fl_str_mv |
The effectiveness of dexamethasone on the prognosis of dialysis patients with severe COVID-19 |
title |
The effectiveness of dexamethasone on the prognosis of dialysis patients with severe COVID-19 |
spellingShingle |
The effectiveness of dexamethasone on the prognosis of dialysis patients with severe COVID-19 Toçoglu,Aysel Chronic kidney disease COVID-19 Dexamethasone Dialysis Mortality |
title_short |
The effectiveness of dexamethasone on the prognosis of dialysis patients with severe COVID-19 |
title_full |
The effectiveness of dexamethasone on the prognosis of dialysis patients with severe COVID-19 |
title_fullStr |
The effectiveness of dexamethasone on the prognosis of dialysis patients with severe COVID-19 |
title_full_unstemmed |
The effectiveness of dexamethasone on the prognosis of dialysis patients with severe COVID-19 |
title_sort |
The effectiveness of dexamethasone on the prognosis of dialysis patients with severe COVID-19 |
author |
Toçoglu,Aysel |
author_facet |
Toçoglu,Aysel Dheir,Hamad Demirci,Taner Kurt,Rumeysa Salihi,Salih Yaylaci,Selçuk Çakar,Gözde Çakırsoy Toptan,Hande Karabay,Oguz Sipahi,Savas |
author_role |
author |
author2 |
Dheir,Hamad Demirci,Taner Kurt,Rumeysa Salihi,Salih Yaylaci,Selçuk Çakar,Gözde Çakırsoy Toptan,Hande Karabay,Oguz Sipahi,Savas |
author2_role |
author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Toçoglu,Aysel Dheir,Hamad Demirci,Taner Kurt,Rumeysa Salihi,Salih Yaylaci,Selçuk Çakar,Gözde Çakırsoy Toptan,Hande Karabay,Oguz Sipahi,Savas |
dc.subject.por.fl_str_mv |
Chronic kidney disease COVID-19 Dexamethasone Dialysis Mortality |
topic |
Chronic kidney disease COVID-19 Dexamethasone Dialysis Mortality |
description |
SUMMARY OBJECTIVE: This study aimed to investigate the effectiveness of dexamethasone in dialysis patients with COVID-19 and whether it predicts mortality. METHODS: This is a comparative cross-sectional study of 113 consecutive patients with COVID-19 with severe pneumonia signs. The patients were divided into two groups according to the use of dexamethasone treatment: group 1 (n=45) included patients who were treated with dexamethasone and group 2 (n=68) who did not receive dexamethasone. RESULTS: The mean age of both groups was 67.0±10.6 and 67.2±13.0 years, respectively (p=0.947). With respect to demographic and laboratory findings, there were no significant differences between the two groups (p>0.05). The hospitalization time of patients in group 1 was longer than that in group 2 (11 [7–17] days vs. 8 [5.3–14] days, p=0.093]. The 28-day survival rate was 54.2% in the group receiving dexamethasone treatment and 79.5% in the group not receiving dexamethasone treatment (p=0.440). CONCLUSION: Dexamethasone did not reduce mortality rates and the requirement for intensive care unit in dialysis patients with COVID-19. Larger prospective randomized clinical trials are required to associate personalized medicine with the corticosteroid treatment to select suitable patients who are more likely to show a benefit. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-09-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302021001001299 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302021001001299 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/1806-9282.20210600 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Associação Médica Brasileira |
publisher.none.fl_str_mv |
Associação Médica Brasileira |
dc.source.none.fl_str_mv |
Revista da Associação Médica Brasileira v.67 n.9 2021 reponame:Revista da Associação Médica Brasileira (Online) instname:Associação Médica Brasileira (AMB) instacron:AMB |
instname_str |
Associação Médica Brasileira (AMB) |
instacron_str |
AMB |
institution |
AMB |
reponame_str |
Revista da Associação Médica Brasileira (Online) |
collection |
Revista da Associação Médica Brasileira (Online) |
repository.name.fl_str_mv |
Revista da Associação Médica Brasileira (Online) - Associação Médica Brasileira (AMB) |
repository.mail.fl_str_mv |
||ramb@amb.org.br |
_version_ |
1754212836561649664 |